Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Alphabet Inc Class A — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Alphabet Inc Class A trades at $361.69 (market cap $4.46T). The key difference: Alphabet Inc Class A is far larger — about 993.3× ACADIA Pharmaceuticals Inc.'s market cap, and Alphabet Inc Class A pays a 0.24% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | GOOGL | |
|---|---|---|
Market Cap | $4.49B | $4.46T |
Sector | Health | Media |
52-Week High | $28.06 | $402.62 |
52-Week Low | $20.06 | $174.36 |
Enterprise Value | $3.69B | $4.42T |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Alphabet (GOOGL) trades at $361.87, down 1.25% over 24 hours, with a bullish technical signal from moving averages. The stock shows strong fundamentals with Q1 2026 EPS of $5.11 beating expectations, revenue growth to $402.84 billion in 2025, and robust profitability margins. Recent news highlights AI-driven growth opportunities, including partnerships and YouTube price increases.
Outlook remains positive with an 85% analyst buy rating and $431.35 consensus price target, implying 19% upside. Key risks include antitrust scrutiny and tech sector volatility. The combination of earnings momentum, AI leadership, and institutional support suggests a favorable risk-reward profile for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
